JP5422570B2 - 凝固第Xa因子及びトロンビンの阻害剤としてのクロロチオフェン−アミド類 - Google Patents
凝固第Xa因子及びトロンビンの阻害剤としてのクロロチオフェン−アミド類 Download PDFInfo
- Publication number
- JP5422570B2 JP5422570B2 JP2010547079A JP2010547079A JP5422570B2 JP 5422570 B2 JP5422570 B2 JP 5422570B2 JP 2010547079 A JP2010547079 A JP 2010547079A JP 2010547079 A JP2010547079 A JP 2010547079A JP 5422570 B2 JP5422570 B2 JP 5422570B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkylene
- independently
- unsubstituted
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(C)(C1)C(C)(*)/C=C/C(C)(*)/C=C1/N Chemical compound CC(C)(C1)C(C)(*)/C=C/C(C)(*)/C=C1/N 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D333/40—Thiophene-2-carboxylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08290279.2 | 2008-02-21 | ||
| EP08290279 | 2008-02-21 | ||
| PCT/EP2009/000903 WO2009103440A1 (en) | 2008-02-21 | 2009-02-10 | Chlorothiophene-amides as inhibitors of coagulation factors xa and thrombin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011512368A JP2011512368A (ja) | 2011-04-21 |
| JP2011512368A5 JP2011512368A5 (enExample) | 2012-03-29 |
| JP5422570B2 true JP5422570B2 (ja) | 2014-02-19 |
Family
ID=39637695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010547079A Expired - Fee Related JP5422570B2 (ja) | 2008-02-21 | 2009-02-10 | 凝固第Xa因子及びトロンビンの阻害剤としてのクロロチオフェン−アミド類 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8378092B2 (enExample) |
| EP (1) | EP2254881B1 (enExample) |
| JP (1) | JP5422570B2 (enExample) |
| CN (1) | CN102015675B (enExample) |
| AR (1) | AR070441A1 (enExample) |
| AU (1) | AU2009217075B2 (enExample) |
| CA (1) | CA2714654A1 (enExample) |
| CL (1) | CL2009000367A1 (enExample) |
| DK (1) | DK2254881T3 (enExample) |
| ES (1) | ES2394550T3 (enExample) |
| PA (1) | PA8816101A1 (enExample) |
| PE (1) | PE20091729A1 (enExample) |
| PT (1) | PT2254881E (enExample) |
| TW (1) | TW200948366A (enExample) |
| UY (1) | UY31666A1 (enExample) |
| WO (1) | WO2009103440A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012162365A1 (en) | 2011-05-25 | 2012-11-29 | Bristol-Myers Squibb Company | Substituted sulfonamides useful as antiapoptotic bcl inhibitors |
| CN102924442B (zh) * | 2012-11-15 | 2014-10-29 | 沈阳药科大学 | 含有噻唑环的色满类化合物及其类似物和医药用途 |
| KR102388926B1 (ko) * | 2013-04-26 | 2022-04-22 | 베이징 리앤신 파마수티컬 씨오., 엘티디. | 5-클로로-티오펜-2-카복실산 [(s)-2-[메틸-3-(2-옥소-피롤리딘-1-일)-벤젠설포닐아미노]-3-(4-메틸 피페라진-1-일)-3-옥소-프로필]아미드의 타르트레이트 염 |
| CN104557928B (zh) * | 2015-02-14 | 2016-08-24 | 佛山市赛维斯医药科技有限公司 | 一种含二环酰胺结构凝血因子Xa抑制剂、其制备方法及其用途 |
| US9701671B2 (en) * | 2015-02-20 | 2017-07-11 | Canon Kabushiki Kaisha | Organic compound, electrochromic element containing the same, optical filter, lens unit, imaging device, and window component |
| WO2017030987A1 (en) * | 2015-08-14 | 2017-02-23 | The Broad Institute, Inc. | Compositions and methods for treating multiple myeloma |
| US20250002483A1 (en) | 2021-09-03 | 2025-01-02 | Bayer Aktiengesellschaft | Substituted s-alaninate derivatives |
| WO2024175450A1 (en) | 2023-02-21 | 2024-08-29 | Bayer Aktiengesellschaft | Substituted s-alaninate derivatives |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9322976D0 (en) * | 1993-11-08 | 1994-01-05 | Pfizer Ltd | Therapeutic agents |
| US6313242B1 (en) * | 1996-05-20 | 2001-11-06 | Fina Technology, Inc. | Stereorigid bis-fluorenyl metallocenes |
| JP2001512439A (ja) * | 1997-02-06 | 2001-08-21 | メルク エンド カンパニー インコーポレーテッド | 線維素原受容体拮抗薬プロドラッグ |
| US6274620B1 (en) * | 1999-06-07 | 2001-08-14 | Biochem Pharma Inc. | Thiophene integrin inhibitors |
| WO2001038309A1 (en) | 1999-11-24 | 2001-05-31 | Cor Therapeutics, Inc. | β-AMINO ACID-, ASPARTIC ACID- AND DIAMINOPROPIONIC-BASED INHIBITORS OF FACTOR Xa |
| GB0228552D0 (en) * | 2002-12-06 | 2003-01-15 | Glaxo Group Ltd | Chemical compounds |
| WO2004058728A1 (ja) | 2002-12-24 | 2004-07-15 | Daiichi Pharmaceutical Co., Ltd. | 新規なエチレンジアミン誘導体 |
| WO2007056056A2 (en) | 2005-11-02 | 2007-05-18 | Cytokinetics, Inc. | Mitotic kinesin inhibitors |
-
2009
- 2009-02-10 EP EP09712426A patent/EP2254881B1/en active Active
- 2009-02-10 CA CA2714654A patent/CA2714654A1/en not_active Abandoned
- 2009-02-10 PT PT97124267T patent/PT2254881E/pt unknown
- 2009-02-10 ES ES09712426T patent/ES2394550T3/es active Active
- 2009-02-10 JP JP2010547079A patent/JP5422570B2/ja not_active Expired - Fee Related
- 2009-02-10 WO PCT/EP2009/000903 patent/WO2009103440A1/en not_active Ceased
- 2009-02-10 CN CN200980114013.9A patent/CN102015675B/zh active Active
- 2009-02-10 DK DK09712426.7T patent/DK2254881T3/da active
- 2009-02-10 AU AU2009217075A patent/AU2009217075B2/en not_active Ceased
- 2009-02-16 PA PA20098816101A patent/PA8816101A1/es unknown
- 2009-02-18 CL CL2009000367A patent/CL2009000367A1/es unknown
- 2009-02-19 TW TW098105198A patent/TW200948366A/zh unknown
- 2009-02-19 PE PE2009000243A patent/PE20091729A1/es not_active Application Discontinuation
- 2009-02-19 AR ARP090100576A patent/AR070441A1/es unknown
- 2009-02-19 UY UY031666A patent/UY31666A1/es not_active Application Discontinuation
-
2010
- 2010-08-18 US US12/858,991 patent/US8378092B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011512368A (ja) | 2011-04-21 |
| UY31666A1 (es) | 2009-09-30 |
| CN102015675B (zh) | 2014-07-02 |
| EP2254881B1 (en) | 2012-09-12 |
| AU2009217075A1 (en) | 2009-08-27 |
| EP2254881A1 (en) | 2010-12-01 |
| CN102015675A (zh) | 2011-04-13 |
| HK1156607A1 (en) | 2012-06-15 |
| WO2009103440A1 (en) | 2009-08-27 |
| CL2009000367A1 (es) | 2009-06-26 |
| AR070441A1 (es) | 2010-04-07 |
| US20110112075A1 (en) | 2011-05-12 |
| US8378092B2 (en) | 2013-02-19 |
| DK2254881T3 (da) | 2012-12-10 |
| PA8816101A1 (es) | 2009-09-17 |
| PE20091729A1 (es) | 2009-12-01 |
| PT2254881E (pt) | 2012-12-10 |
| AU2009217075B2 (en) | 2013-05-16 |
| TW200948366A (en) | 2009-12-01 |
| CA2714654A1 (en) | 2009-08-27 |
| ES2394550T3 (es) | 2013-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5422570B2 (ja) | 凝固第Xa因子及びトロンビンの阻害剤としてのクロロチオフェン−アミド類 | |
| JP4861306B2 (ja) | Xa因子阻害剤としてのピロール誘導体 | |
| JP4709763B2 (ja) | 第Xa因子阻害剤としてのインダゾール誘導体 | |
| KR20060136457A (ko) | 인자 Xa 억제제로서의 피롤-유도체 | |
| JP4608495B2 (ja) | 第Xa因子阻害剤としてのトリアゾール誘導体 | |
| JP5422569B2 (ja) | 凝固第Xa因子及びトロンビンの阻害剤としてのクロロチオフェン−イソオキサゾール類 | |
| JP4658940B2 (ja) | 第Xa因子阻害剤としてのベンゾイミダゾール誘導体 | |
| MXPA05005498A (es) | Derivados de imidazol como inhibidores del factor xa. | |
| JP4733642B2 (ja) | 第Xa因子阻害剤としてのアザインドール−誘導体 | |
| JP5027802B2 (ja) | 第Xa因子阻害剤としてのヘテロアリール−カルボン酸(スルファモイルアルキル)アミド−誘導体 | |
| HK1156607B (en) | Chlorothiophene-amides as inhibitors of coagulation factors xa and thrombin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120206 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120206 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131029 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131125 |
|
| LAPS | Cancellation because of no payment of annual fees |